Teladoc Health, Inc. TDOC

Rank #1497 · NYSE · $1.5B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

47.5

P/E

-7.0

P/B

0.67

ROE

-9.5%

Op. Margin

-9.6%

Debt Ratio

88%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆

Average

P/E -7.0x, P/B 0.67x. Ranks in the top 48% of the universe.

Profitability ★☆☆☆☆

Weak

ROE -9.5%. Ranks in the top 77% of the universe.

Safety ★★★☆☆

Good

Debt ratio 88%. Ranks in the top 35% of the universe.

Growth ★★★☆☆

Good

Revenue growth of 8.1% year over year. Ranks in the top 40% of the universe.

Valuation is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	$0.0B	$-0.0B	$-0.0B	$-0.0B	-29.5	-297
2016	$0.0B	$-0.0B	$-0.0B	$-0.1B	-34.8	-514
2017	$0.1B	$-0.1B	$-0.1B	$-0.1B	-72.1	-550
2018	$0.1B	$-0.1B	$-0.1B	$0.2B	-50.9	362
2019	$0.2B	$-0.1B	$-0.1B	$1.0B	-32.3	51
2020	$0.4B	$-0.1B	$-0.1B	$0.6B	-17.0	187
2021	$0.6B	$-0.1B	$-0.1B	$1.0B	-14.5	1653
2022	$1.1B	$-0.5B	$-0.5B	$1.0B	-46.3	1649
2023	$2.0B	$-0.3B	$-0.4B	$15.9B	-13.1	-73
2024	$2.4B	$-13.7B	$-13.7B	$16.0B	-567.3	13
2025	$2.6B	$-0.2B	$-0.2B	$2.3B	-9.6	88